Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C64761
http://purl.obolibrary.org/obo/NCIT_C64761
Preferred Name

CDK Inhibitor AT7519
Definitions
An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some types of cancer cells.
prefLabel
CDK Inhibitor AT7519
label
CDK Inhibitor AT7519
PDQ_Closed_Trial_Search_ID
513177
code
C64761
Has_Target
prefixIRI
NCIT:C64761
in_subset
Display_Name
CDKI AT7519
Preferred_Name
CDK Inhibitor AT7519
FDA_UNII_Code
X1BF92PW9T
Contributing_Source
CTRP
FDA
Chemical_Formula
C16H17Cl2N5O2
Maps_To
CDK Inhibitor AT7519
CAS_Registry
844442-38-2
NCI_Drug_Dictionary_ID
513177
Legacy Concept Name
AT7519M
type
ALT_DEFINITION
A substance being studied in the treatment of some types of cancer. AT7519M blocks enzymes needed for cells to divide. It is a type of cyclin-dependent kinase inhibitor.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
513177
Semantic_Type
Organic Chemical
Pharmacologic Substance
UMLS_CUI
C1879520
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display